Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leukemia

This publication has 24 references indexed in Scilit:

• Imatinib Mesylate — Uncovering a Fast Track to Adaptive Immunity
  New England Journal of Medicine, 2006
• Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
  Blood, 2006
• High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group
  Journal of Clinical Oncology, 2006
• Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
  Blood, 2005
• Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation
  Transplantation and Cellular Therapy, 2004
• Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
  Leukemia, 2003
• Predictors of relapse and overall survival in Philadelphia chromosome–positive acute lymphoblastic leukemia after transplantation
  Transplantation and Cellular Therapy, 2003
• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
  New England Journal of Medicine, 2003
• Predictors of relapse and overall survival in Philadelphia chromosome[ndash ]positive acute lymphoblastic leukemia after transplantation
  Transplantation and Cellular Therapy, 2003
• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
  Blood, 2002